NASDAQ · WGS
GeneDx Holdings Corp.
$68.18-$2.84 (-4.0%)
GeneDx Holdings Corp.’s quoted price sits in the lower half of its reported 52-week range, 60.1% below the high.
Loading market information…
NASDAQ · MGRM · USD
Stock price, earnings
Quote as of Oct 7, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Monogram Orthopaedics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.61% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Monogram Orthopaedics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Monogram Orthopaedics, Inc. (MGRM) specializes in developing technologies that enable the mass personalization and optimization of orthopedic implants. The company's strategy involves producing and marketing a comprehensive array of tools for reconstructive joint replacement surgeries, including advanced robotic surgical equipment with integrated software, specialized orthopedic implants, tissue ablation instruments, navigation consumables, and other related surgical accessories. Demonstrating its capabilities, a prototype robot precisely places optimized implants into synthetic bone specimens by executing carefully planned surgical pathways. The company was founded in 2016 and was initially known as Monogram Arthroplasty Inc. before officially rebranding to Monogram Orthopaedics, Inc. in March 2017. Its corporate headquarters are located in Austin, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:07 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 |
|---|
| Mar 15, 2024 |
| -$0.09 |
| $365.00K |
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$68.18-$2.84 (-4.0%)
GeneDx Holdings Corp.’s quoted price sits in the lower half of its reported 52-week range, 60.1% below the high.
$34.42+$0.17 (+0.5%)
Sonida Senior Living, Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.46% below the high.
$4.00+$0.01 (+0.25%)
Inozyme Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 35.9% below the high.
$5.38-$0.01 (-0.09%)
Third Harmonic Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.42% below the high.
$6.39-$0.13 (-2.0%)
Lifecore Biomedical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 28.85% below the high.
$2.27$0.00 (0.0%)
Acelyrin, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.69% below the high.
$5.84$0.00 (0.0%)
Nevro Corp.’s quoted price sits in the lower half of its reported 52-week range, 56.09% below the high.
$6.10+$1.65 (+37.08%)
BioSig Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.77% below the high.
